

RECEIVED
CENTRAL FAX CENTER

APR 3 0 2004

P&G Case 9533

THE ONITED STATES PATENT AND TRADEMARK OFFICE

In the application of

Donald C. Roe et al.

Serial No. 10/811,696

Filed March 29, 2004

Confirmation No.

Group Art Unit

Examiner

For Disposable Absorbent Articles Being Adaptable To Wearer's Anatomy

### INFORMATION DISCLOSURE STATEMENT

Commissioner for Patents
P. O. Box 1450

Alexandria, VA 22313-1450

Dear Sir.

Pursuant to 37 C.F.R. §§ 1.56, 1.97 and 1.98, record is being made on the attached Form PTO/SB08 of documents which the Patent Office may wish to consider in connection with examination of the above-identified patent application. It is respectfully requested that the cited documents be carefully considered by the Examiner and made of record in this case. As provided in §1.97(g), no representation is made or intended that a thorough art search was made. As provided in 37 C.F.R. §1.97(h), this Information Disclosure Statement does not constitute an admission of any kind, and specifically is not an admission that the documents listed on attached form PTO/SB08 are, or are considered to be, material to the patentability of the above-identified patent application, as defined in 37 C.F.R. §1.56(b).

1. [X] 37 C.F.R. \$1.97(b)(1) - U.S. Direct (use when filing IDS with nonprovisional patent application, or with Request for Continued Examination (RCE); or within 3 months of filing a nonprovisional patent application)

This information disclosure statement, submitted under 37 C.F.R. §1.97(b)(1), is being filed with the patent application, with a Request for Continued Examination or within three months of the filing date of a national application. Therefore, no fee is believed to be due.

## 2. [] 37 C.F.R. §1.97(b)(3) - (use when filing IDS more than 3 months after filing a nonprovisional patent application, but prior to receipt of first Office Action)

This information disclosure statement is being submitted under 37 C.F.R. §1.97(b)(3). Applicants have not received an Office Action on the merits in the present application. Therefore, no fee is believed to be due. However, in the event that this paper is crossing in the mail with a first Office Action on the merits, authorization is hereby given to charge the required fee pursuant to 37 C.F.R. §1.97(c) and 37 C.F.R. §1.17(p) to Deposit Account No. 16-2480 in the name of The Procter & Gamble Company. A duplicate of this letter (or a fee transmittal form) is enclosed to facilitate charging of the fee, if necessary.

## 3. [] 37 C.F.R. §1.97(b)(4) - (use when filing IDS prior to receipt of first Office Action after the filing of a Request for Continued Examination (RCE) under §1.114)

This information disclosure statement is being submitted under 37 C.F.R. §1.97(b)(4). Applicants have not received a first Office Action after filing a Request For Continued Examination (RCE). Therefore, no fee is believed to be due. However, in the event that this paper is crossing in the mall with a first Office Action on the merits, authorization is hereby given to charge the required fee pursuant to 37 C.F.R. §1.97(c) and 37 C.F.R. §1.17(p) to Deposit Account No. 16-2480 in the name of The Procter & Gamble Company. A duplicate of this letter (or a fee transmittal form) is enclosed to facilitate charging of the fee, if necessary.

# 4. [] 37 C.F.R. §1.97(c) with fee payment - (use when filing IDS after receipt of first Office Action, and before receipt of Final Office Action, Notice of Allowance, or an action that otherwise closes prosecution)

This information disclosure statement is being submitted under 37 C.F.R. §1.97(c). Applicant(s) have not received a final action under 37 C.F.R. §1.113, a notice of allowance under 37 C.F.R. §1.311, or an action that otherwise closes prosecution in the application (e.g., Ex parte Quayle) as of the date of this submission. Applicant(s) elect to pay the fee set forth in 37 C.F.R. §1.17(p). Please charge the fee set forth in 37 C.F.R. §1.17(p) to Deposit Account Number 16-2480 in the name of The Procter & Gamble Company. A duplicate copy of this letter (or a fee transmittal form) is enclosed to facilitate the charging of the fee.

5. [] Information to be Considered with Continued Prosecution Application (CPA) Filing (use when filing IDS with a Continued Prosecution Application (CPA) for Design Case). This information disclosure statement is being filed with a Continued Prosecution Application (CPA) filed under 37 C.F.R. 1.53(d).

### ADDITIONAL ITEMS TO BE NOTED BY THE EXAMINER:

[X] (2) (For use with applications filed after June 30, 2003.) In accordance with
[X] (2) (For use with applications and constructions) (2) (For use with applications) (3) (2), Applicants are submitting copies of foreign patent documents and non-
patent literature.  OR
[] (3) All of the cited references were previously cited by or submitted to the USPTO in prior application Case No, U.S. Patent Application Serial No, filed Applicants claim priority to said application under 35 U.S.C. §120. Accordingly, copies of previously submitted references are not provided with this Statement, pursuant to 37 C.F.R. §1.98(d). It is respectfully requested that the cited documents be carefully considered by the Examiner and
made of record in this case.  OR
[] (4) Copies of all said documents, except Cite Numbers, were submitted and considered in parent application U.S. Patent Application Serial No, filed and considered in parent application U.S. Patent Application under 35 U.S.C. §120. Accordingly, Applicant(s) claim priority to said application under 35 U.S.C. §120. Accordingly, copies of previously submitted references are not provided with this Statement, pursuant to 37 C.F.R. §1.98(d). Copies of references not previously submitted are enclosed. It is respectfully requested that the cited documents be carefully considered by the Examiner and made of record in this case.
[] (5) Pursuant to 37 C.F.R. §1.98(c), a concise explanation of the relevance of each cited
reference that is not in the English language is provided.
[] (6) Applicants also respectfully request the Examiner to consider and make of record the co-pending applications listed on the attached page.
Additional information is attached.  Respectfully submitted.
Date: 4/26/64  Customer No. 27752 (IDS.doc) (Last Revised 10/10/03)  By  Jack L. Oney, Jr.  Attorney for Applicant(s)  Registration No. 42,964  (513) 626-3047

Please type a plus sign (+) inside this box  $\rightarrow$  [+]

PTO/SB08A (08-03)

U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Substitute for form 1449A/PTO	complete if known		
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary)	Application Number	10/811,696	
	Confirmation Number		
	Filing Date	March 29, 2004	
	First Named Inventor	Mark J. Kline	
	Group Art Unit		
	Examiner Name		
SHEET 1 of 2	Attorney Docket Number	9533	

### U. S. PATENT DOCUMENTS

XAMINER	Cite No.1	DOCUMENT NUMBER	Publication Date MM-DE-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines Where Relevant Passages of Relevant Figures Appear
		Number - Kind Code <sup>3</sup> (if known)	11-19-1974	Buell	
		US-3,848,594	01-14-1975	Buell	
		US-3,860,003	09-09-1986	Weisman et al.	
		US-4,610,678	05-05-1987	Hirotsu et al.	
	<u> </u>	US-4,662,875	06-16-1987	Weisman et al.	
	<u> </u>	US-4,673,402	10-13-1987	Toussant et al.	
	<u> </u>	US-4,699,622	05-30-1989	Alemany et al.	
		US-4,834,735	07-11-1989	Scripps	
	1	US-4.846,815	12-19-1989	Angstadt	
		US-4,888,231	01-09-1990	DesMarais et al.	
		US-4,892,536	01-16-1990	Nestegard	
		US-4,894,060	07-10-1990	Van Gompel et al.	
		US-4,940,464	08-07-1990	Battrell	
		US-4.946,527	10-16-1990	Robertson et al.	
	<b>_</b>	US-4,963,140	02-05-1991	Freeland	
		US-4,990,147	08-06-1991	Allen et al.	
-	<u> </u>	US-5,037,416	03-03-1992	Nomura et al.	
		US-5,092,861		Herron et al.	
		US-5,137,537	08-11-1992	Young et al.	
		US-5,147,345	09-15-1992 09-09-1992	Buell	
		US-5,151,092		Buell et al.	
		US-5,156,793	10-20-1992	Weber et al.	
		U\$-5,167,897	12-01-1992	Buell	
		US- <u>5,221,274</u>	06-22-1993	Weil et al.	
		US-5,242,436	09-07-1993	Hasse et al.	
		US-5,246,433	09-21-1993	DesMarais et al.	
		US-5,260,345	11-09-1993	Freeland et al.	
		US-5,269.77 <u>5</u>	12-14-1993	Roe	
		US-5,342,338	08-30-1994	Dver et al.	
	7	US-5,387,207	02-07-1995	LaVon et al.	
		US-5,397,316	03-14-1995	Buell et al.	
		US-5,499,978	03-19-1996	Clear et al.	
		US-5,507,736	04-16-1996	Roe et al.	
		US-5,554,143	09-10-1996	Roe et al.	
		US-5,554,144	09-10-1996	Roe et al.	
		US-5,554,145	09-10-1996	Roe et al.	
		US-5,556,394	09-17-1996	Buell et al.	
		US-5,569,232	10-29-1996	Buell et al.	
		US-5,569,234	10-29-1996	Dobrin et al.	<del>                                     </del>
	1	US-5,571,096	11-05-1996		<del></del>
		U\$-5,575,783	11-19-1996	Clear et al.	<u> </u>
		U\$-5,580,411	12-03-1996	Nease et al.	
	$\neg$	US-5,591,152	01-07-1997	Buell et al.	<del>                                     </del>
	1	U\$-5,625,222	07-22-1997	DesMarais et al.	
		US-5,749,866	05-12-1998	Roe et al.	
	_	US-5,865,823	02-02-1999	Curro	
	$\dashv$	US-5,876,391	03-02-1999	Roe et al.	
	+	US-5,897,545	04-27-1999	Kline et al.	
		US-5,904,673	05-18-1999	Roe et al.	

US-5,916,663	06-29-1999	Chappell et al.	
 US-5,957,908	09-28-1999	Kline et at.	
 US-6,004,306	12-21-1999	Robles et al.	
 US-6,107,537	08-22-2000	Elder et al.	
US-6,120,487	09-19-2000	Ashton	
 US-6,120,489	09-19-2000	Johnson et al.	
 U\$-6,325,787	12-04-2001	Roe et al.	
 US-6,432,098	08-13-2002	Kline et al.	
US-6,503,236	01-07-2003	Uitenbroek et al.	
 US-6,552,245	04-22-2003	Roessler et al.	
 US-6,585,713	07-01-2003	LeMahieu et al.	
 US-2003/0233082 A1	12-18-2003	Kline et al.	
 US-2003/0088228 A1	05-08-2003	Desai et al.	
US-			

#### **FOREIGN PATENT DOCUMENTS**

EXAMINER INITIALS	Cite No.	FOREIGN PATENT DO  Country Code <sup>8</sup> Number <sup>4</sup>	Kind Code <sup>5</sup> (if known)	Publication Date	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines Where Relevant Passages or Relevant Figures Appear	T <sup>6</sup>
		WO 95/16746 A1		06-22-1995	E.I. DuPont De Nemours and Company		
	_						
EXAMINE	R				DATE CONSIDERED		

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

'Applicant's unique citation designation number (optional). See Kind Codes of U.S. Patent Documents at <a href="www.uspto.gov">www.uspto.gov</a> or MPEP 901.04. Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 37 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

PTO-SB08 (Revised for P&G use 10/8/2003)